Genenta Science S.p.A.

NasdaqCM GNTA

Genenta Science S.p.A. Net Income Margin for the year ending December 31, 2023

Genenta Science S.p.A. Net Income Margin is NA for the year ending December 31, 2023. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: GNTA

Genenta Science S.p.A.

CEO	Mr. Pierluigi Paracchi
IPO Date	Dec. 15, 2021
Location	Italy
Headquarters	Via Olgettina No. 58
Employees	14
Sector	Healthcare
Industries Biotechnology

Description

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Key trends

Past 5 years